| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6962908 | APIL | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Dec, 2021
(2 years ago) | |
| US7799771 | APIL | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Dec, 2021
(2 years ago) | |
| US7572779 | APIL | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Oct, 2025
(1 year, 5 months from now) | |
Femtrace is owned by Apil.
Femtrace contains Estradiol Acetate.
Femtrace has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Femtrace are:
- US6962908
- US7799771
Femtrace was authorised for market use on 20 August, 2004.
Femtrace is available in tablet;oral dosage forms.
Femtrace can be used as treatment of moderate to severe vasomotor symptoms associated with menopause.
The generics of Femtrace are possible to be released after 02 October, 2025.
Drugs and Companies using ESTRADIOL ACETATE ingredient
Market Authorisation Date: 20 August, 2004
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
More Information on Dosage
FEMTRACE family patents
